---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-030184"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2025-10-01T23:59:59+00:00"
generated_at: "2026-05-17T05:05:29.821533+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences stockholders approve equity plan amendment and ratify director options

## Summary
- Stockholders approved increasing Equity Plan shares by 2 million and changing Consultant definition.
- Ratified options for up to 1.1 million shares, including 600,000 to directors (CEO LaViolette).
- Director options have exercise price $15.65, 10-year term, vesting over annual meeting and monthly.
- Proposal 1 voted 50,247,945 For vs 2,753,901 Against; Proposal 2 similarly approved.
- Special Meeting held Sept 30, 2025; quorum of 53,011,701 shares represented.

## SEC filing metadata
- accession: 0001437749-25-030184
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2025-10-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.07, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774925030184/0001437749-25-030184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774925030184/plse20250929_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-030184
- JSON: https://secwatch.observer/filing/0001437749-25-030184.json
- Plain text: https://secwatch.observer/filing/0001437749-25-030184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.